A share price of Bio-Techne Corp [TECH] is currently trading at $75.31, up 2.12%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TECH shares have gain 9.65% over the last week, with a monthly amount glided 1.77%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Bio-Techne Corp [NASDAQ: TECH] stock has seen the most recent analyst activity on May 22, 2024, when Citigroup downgraded its rating to a Neutral but kept the price target unchanged to $85 for it. Previously, Scotiabank started tracking the stock with Sector Outperform rating on February 08, 2024, and set its price target to $80. On February 02, 2024, downgrade downgraded it’s rating to Hold but maintained its price target of $65 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $80 on December 07, 2023. William Blair initiated its recommendation with a Outperform. Wells Fargo upgraded its rating to Equal Weight for this stock on January 10, 2023, but kept the price target unchanged to $90. In a note dated December 14, 2022, Deutsche Bank initiated an Buy rating and provided a target price of $100 on this stock.
Bio-Techne Corp experienced fluctuations in its stock price throughout the past year between $51.79 and $85.57. Currently, Wall Street analysts expect the stock to reach $91.69 within the next 12 months. Bio-Techne Corp [NASDAQ: TECH] shares were valued at $75.31 at the most recent close of the market. An investor can expect a potential return of 21.75% based on the average TECH price forecast.
Analyzing the TECH fundamentals
Trailing Twelve Months sales for Bio-Techne Corp [NASDAQ:TECH] were 1.17B which represents 4.52% growth. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.07 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 74.07 points at the first support level, and at 72.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 76.56, and for the 2nd resistance point, it is at 77.80.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Bio-Techne Corp [NASDAQ:TECH] is 4.56. As well, the Quick Ratio is 3.26, while the Cash Ratio is 1.32. Considering the valuation of this stock, the price to sales ratio is 10.41, the price to book ratio is 5.76 and price to earnings (TTM) ratio is 80.13.
Transactions by insiders
Recent insider trading involved BAUMGARTNER ROBERT V, Director, that happened on Aug 08 ’24 when 16000.0 shares were sold. Director, ROBERT V. BAUMGARTNER completed a deal on Aug 08 ’24 to buy 16000.0 shares. Meanwhile, Director HIGGINS JOHN L sold 4000.0 shares on May 14 ’24.
